News & Updates

Patients who present with second primary melanomas have better survival and thinner lesions than those presenting with single primary melanomas, reveals a study.

Developing cutaneous immune-related adverse events (cirAEs) among advanced cancer patients on immune checkpoint inhibitor (ICI) appears to be a sign of longer overall survival, particularly in those with melanoma, suggests a recent study.

Targeting interleukin (IL)-13 with tralokinumab monotherapy helps reduce disease activity in adolescents with moderate-to-severe atopic dermatitis (AD) with a low frequency of conjunctivitis throughout the treatment period, according to data from the phase III ECZTRA 6 trial.

The prescribing patterns for acne among local primary care physicians appear to deviate from clinical practice guidelines used to achieve optimal outcomes for young people, as shown in a Singapore study.

Treatment with apremilast demonstrates consistent efficacy in genital psoriasis and overall psoriasis symptoms at 16 weeks irrespective of body surface area (BSA) at baseline, suggest the results of the phase III DISCREET trial presented at the recent AAD 2023.

Treatment with lebrikizumab with or without topical corticosteroids (TCS) results in clinical improvement among adolescents with moderate-to-severe atopic dermatitis (AD), according to a study presented at the recent AAD 2023.

Data presented at AAD 2023 underpin the potential of upadacitinib, a selective Janus kinase inhibitor, to provide long-term improvements in patient-reported outcomes (PROs; skin symptoms, sleep, and quality of life [QoL]) in individuals with moderate-to-severe atopic dermatitis (AD).